Aveva’s only approved generic version of ZTlido has moved closer to potential US market entry after the Federal Circuit upheld a finding that its lidocaine patch does not infringe three Scilex patents.
Aveva’s only approved generic version of ZTlido has moved closer to potential US market entry after the Federal Circuit upheld a finding that its lidocaine patch does not infringe three Scilex patents.